Flavocure Biotech

Flavocure Biotech is a private, preclinical-stage biotech founded in 2018 and headquartered in Baltimore, MD. The company is developing a novel NanoCaflanone™ theranostic platform designed to deliver drugs across the blood-brain barrier, targeting neuroinflammation in diseases like Alzheimer's and Parkinson's, as well as tumor-associated macrophages in cancers like pancreatic cancer and glioblastoma. Its lead asset, Caflanone, is IND-ready for pancreatic cancer with FDA Orphan Drug designation, positioning the company to address areas with high mortality and limited treatment options.

NanoCaflanone™, a proprietary theranostic platform designed to deliver drugs across the blood-brain barrier by targeting disease-associated microglia (DAMs) and tumor-associated macrophages (TAMMs) via CSF1-R. Includes a diagnostic variant (NCDx™) as a molecular MRI probe.

Flavocure competes in the crowded and challenging fields of pancreatic cancer, GBM, and neurodegenerative diseases. Its specific approach of CSF1-R inhibition for modulating microglia/macrophages places it against other biotechs and pharma companies exploring immuno-oncology and neuro-immunology. Its key differentiator is the integrated theranostic NanoCaflanone™ platform designed for BBB penetration.